Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? (Q37960410)

26 August 2017

title

Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? (English)

1 reference

26 August 2017

1 reference

Michael Gnant

1

0 references

publication date

1 February 2012

1 reference

26 August 2017

published in

Current Oncology Reports

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

35-43

1 reference

26 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Tumor self-seeding by circulating cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Bisphosphonates: mode of action and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

The backbone of progress--preclinical studies and innovations with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Potential anticancer properties of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Zoledronic acid - a multiplicity of anti-cancer action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Failure of goserelin ovarian ablation in premenopausal women with breast cancer: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Bone turnover across the menopause transition : The role of gonadal inhibins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Factors affecting bone loss around menopause in women without HRT: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Clinical significance of occult metastatic cells in bone marrow of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

A pooled analysis of bone marrow micrometastasis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Oral bisphosphonate use and breast cancer incidence in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Use of bisphosphonates and reduced risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Is cancer a disease of self-seeding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0209-5

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

12 December 2020

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

1 reference

12 December 2020

Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse

1 reference

12 December 2020

Breast-cancer adjuvant therapy with zoledronic acid

1 reference

12 December 2020

High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.

1 reference

12 December 2020

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

1 reference

12 December 2020

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

1 reference

12 December 2020

Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.

1 reference

12 December 2020

Use of bisphosphonates and risk of postmenopausal breast cancer

1 reference

12 December 2020

Long-lasting effect of pamidronate on bone metabolism in osteoporosis after stopping therapy

1 reference

12 December 2020

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

1 reference

12 December 2020

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up

1 reference

12 December 2020

Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer

1 reference

12 December 2020

The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites

1 reference

12 December 2020

Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more

1 reference

12 December 2020

Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.

1 reference

12 December 2020

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

1 reference

12 December 2020

Pregnancy during gonadotrophin-releasing hormone agonist therapy

1 reference

12 December 2020

Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?

1 reference

12 December 2020

10.1007/S11912-011-0209-5

Identifiers

DOI

1 reference

26 August 2017

1 reference